标题
Immunomodulatory effects of anti-angiogenic drugs
作者
关键词
-
出版物
LEUKEMIA
Volume 25, Issue 6, Pages 899-905
出版商
Springer Nature
发表日期
2011-02-25
DOI
10.1038/leu.2011.24
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
- (2010) A. Kreutzman et al. BLOOD
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- VEGF Blockade Inhibits Lymphocyte Recruitment and Ameliorates Immune-Mediated Vascular Remodeling
- (2010) Jiasheng Zhang et al. CIRCULATION RESEARCH
- Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib
- (2010) Ulrike Heider et al. Clinical Lymphoma Myeloma & Leukemia
- The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
- (2010) Julia Salih et al. INTERNATIONAL JOURNAL OF CANCER
- Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
- (2010) J. Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Effects of nilotinib on regulatory T cells: the dose matters
- (2010) Fei Fei et al. Molecular Cancer
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
- (2009) C Alfaro et al. BRITISH JOURNAL OF CANCER
- Control of HIF-1 Expression by eIF2 Phosphorylation-Mediated Translational Repression
- (2009) K. Zhu et al. CANCER RESEARCH
- Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma
- (2009) J. Zhang et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma
- (2009) Michele Moschetta et al. EUROPEAN JOURNAL OF CANCER
- Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
- (2009) B. Blanco et al. HAEMATOLOGICA
- Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+T cells
- (2009) Carsten Berges et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
- (2009) M. Basler et al. JOURNAL OF IMMUNOLOGY
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
- (2009) R. Houben et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells
- (2008) Fei Fei et al. BRITISH JOURNAL OF HAEMATOLOGY
- Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2
- (2008) Kerrington R. Molhoek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
- (2008) R. Weichsel et al. CLINICAL CANCER RESEARCH
- The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
- (2008) Stephen Blake et al. CLINICAL IMMUNOLOGY
- Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
- (2008) Fei Fei et al. EXPERIMENTAL HEMATOLOGY
- Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
- (2008) Cara K. Fraser et al. EXPERIMENTAL HEMATOLOGY
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Proteasome inhibition suppresses essential immune functions of human CD4+T cells
- (2008) Carsten Berges et al. IMMUNOLOGY
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
- (2008) W Zhao et al. LEUKEMIA
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started